Research and Development Investment: Ascendis Pharma A/S vs Alkermes plc

Biopharma R&D: Ascendis vs. Alkermes Investment Trends

__timestamp	Alkermes plc	Ascendis Pharma A/S
Wednesday, January 1, 2014	7753000	19698000
Thursday, January 1, 2015	4019000	40528000
Friday, January 1, 2016	2301000	66022000
Sunday, January 1, 2017	7232000	99589000
Monday, January 1, 2018	68895000	140281000
Tuesday, January 1, 2019	52816000	191621000
Wednesday, January 1, 2020	1946000	260904000
Friday, January 1, 2021	1020000	295867000
Saturday, January 1, 2022	393842000	379624000
Sunday, January 1, 2023	270806000	413454000
Monday, January 1, 2024	245326000	307004000

Unleashing insights

A Decade of Innovation: R&D Investments in Biopharma

In the competitive landscape of biopharmaceuticals, research and development (R&D) investments are pivotal for innovation and growth. Over the past decade, Ascendis Pharma A/S and Alkermes plc have demonstrated contrasting trajectories in their R&D spending. Ascendis Pharma A/S has consistently increased its R&D investments, culminating in a remarkable 1,900% growth from 2014 to 2023. This surge underscores their commitment to pioneering new therapies. In contrast, Alkermes plc experienced a more volatile pattern, with a significant spike in 2022, where their R&D expenses soared by over 3,800% compared to 2014. However, this was followed by a 31% decline in 2023. These trends highlight the dynamic nature of R&D strategies in the biopharma sector, reflecting each company's unique approach to innovation and market adaptation.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025